Ascendis Pharma A/S is a global biopharmaceutical company developing drug candidates for growth hormone deficiency, endocrinology, CNS disorders, infectious diseases, and diabetes. It operates through multiple subsidiaries in Germany and Denmark.
ASND has been in the news recently: Ascendis Pharma's shares dropped over 11% after the company missed earnings expectations and reduced its guidance for Skytrofa, forecasting 2024 sales between 220-240 million euros. The company reported Q2 sales of $38.76 million, falling short of expectations, and projected breakeven for its drug Yorvipath in 2024-2025.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.